Search Results for "losartan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for losartan. Results 1 to 4 of 4 total matches.
Comparison Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
;
frequent monitoring is recommended
Losartan is a substrate of CYP3A4 and 2C9; use with
inducers ...
View the Comparison Table: Some Drugs for HFrEF
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 14, 2021 (Issue 1626)
(Diovan, and generics) are the only ARBs that are
FDA-approved for treatment of heart failure; losartan ...
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF ≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF.
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
body weights.
OTHER DRUGS — The antihypertensive drug losartan
and the triglyceride-lowering drug ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
229.60
Losartan – generic
Cozaar (Merck)
25, 50, 100 mg tabs 50-100 mg once/day
or divided bid
6.70 ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction